Acetazolamide Applications for Respiratory and Metabolic Disorders

Acetazolamide is a non-specific carbonic anhydrase inhibitor whose principal action is to increase renal bicarbonate excretion, thereby inducing a mild metabolic acidosis. This mechanism underpins its established uses in the management of metabolic alkalosis and in the prophylaxis of acute mountain sickness. Over recent decades, attention has shifted to the drug’s ability to modulate respiratory drive and facilitate weaning from mechanical ventilation in patients with chronic obstructive pulmonary disease (COPD) and other causes of ventilatory failure. By reducing serum bicarbonate and pH, acetazolamide can offset post-hypercapnic alkalosis, promote central chemoreceptor sensitivity to CO₂ and modestly increase minute ventilation. Beyond critical care, its off-label roles include amelioration of central sleep apnoea, treatment of obesity hypoventilation syndrome and adjunctive management of certain forms of pulmonary hypertension. Dosing strategies vary widely, from single doses of 250–500 mg up to regimens exceeding 1000 mg daily, reflecting an ongoing need to balance efficacy with tolerability. Adverse effects such as paresthesiae, electrolyte disturbances and, in rare cases, pulmonary oedema or severe acidosis in renal impairment, underscore the importance of careful patient selection and monitoring. Emerging pharmacodynamic models offer the prospect of individualised dosing by accounting for factors such as baseline acid-base status, co-medications and organ function.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Acetazolamide Applications for Respiratory and Metabolic Disorders publication trend

The graph below shows the total number of articles in acetazolamide applications for respiratory and metabolic disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Carbonic anhydrase inhibitor: A compound that blocks the enzyme carbonic anhydrase, reducing bicarbonate reabsorption in the kidney and inducing metabolic acidosis.

Metabolic alkalosis: An acid–base disturbance characterised by elevated blood bicarbonate and increased pH, often delaying liberation from mechanical ventilation.

Minute ventilation: The total volume of gas inhaled or exhaled from the lungs in one minute, calculated as tidal volume multiplied by respiratory rate.

PaCO₂: Partial pressure of carbon dioxide in arterial blood, reflecting the balance between CO₂ production and alveolar ventilation.

Population pharmacodynamic modelling: A mathematical approach to describe and predict drug effects on a population level, accounting for interindividual variability and covariate influences.

References

1. Carbonic anhydrase inhibitors in patients with respiratory failure and metabolic alkalosis: a systematic review and meta-analysis of randomized controlled trials. Critical Care (2018).
2. Population pharmacodynamic model of bicarbonate response to acetazolamide in mechanically ventilated chronic obstructive pulmonary disease patients. Critical Care (2011).
3. Population Pharmacodynamic Modeling and Simulation of the Respiratory Effect of Acetazolamide in Decompensated COPD Patients. PLOS ONE (2014).